We are pleased to announce the successful completion of our executive search for Mabion S.A., resulting in the appointment of Gregor Kawaletz as CEO.

Gregor brings more than 20 years of experience in the CDMO sector, with a strong track record in driving growth, leading organisational transformation, and strengthening market positioning. His career includes senior leadership roles at NextPharma, Catalent, IDT Biologika, Albumedix (now part of Sartorius), and Recipharm, where, as Chief Commercial Officer and President of the Oral Solid Dosage Business Unit, he spearheaded commercial strategy, anticipated key therapeutic trends such as orally delivered biologics and ADCs, and built strong partnerships with global pharma and biotech companies.

“I am honored to join Mabion at such pivotal moment in the biologics CDMO space. The team’s depth of scientific excellence sets a strong foundation for us to expand our global impact together.
Mabion’s future will be defined by our dual strength: excellence in CDMO services and leadership in biosimilar development and manufacturing. With these capabilities deeply rooted in our DNA, we are poised to shape the next chapter of biologics.” said Gregor Kawaletz, CEO of Mabion S.A.

As ExecMind, we sincerely thank the Supervisory Board of Mabion S.A. for the excellent collaboration throughout the process. Their engagement and strategic perspective were invaluable in ensuring a smooth and effective cooperation.

Mabion S.A. is a European CDMO company specialising in developing and manufacturing biopharmaceuticals, with a strong focus on biosimilars and advanced therapies.

At ExecMind, we are proud to support life science organisations in identifying, attracting, and appointing top-tier talent who drive long-term growth and innovation in the sector.

Congratulations to Gregor Kawaletz and the entire Mabion team - we look forward to witnessing the company’s future success under his leadership.